Results 71 to 80 of about 3,886 (197)

Key Role for the Organic Anion Transporters, OAT1 and OAT3, in the in vivo Handling of Uremic Toxins and Solutes

Scientific Reports, 2017
In vitro data indicates that the kidney proximal tubule (PT) transporters of uremic toxins and solutes (e.g., indoxyl sulfate, p-cresol sulfate, kynurenine, creatinine, urate) include two “drug” transporters of the organic anion transporter (OAT) family:
Wei Wu, Kevin T. Bush, Sanjay K. Nigam
doaj   +1 more source

Engineered Microvascular Model of the Blood–Brain–Tumor Barrier Reveals Endothelial Remodeling in Diffuse Midline Glioma

Advanced Healthcare Materials, Volume 15, Issue 37, 9 October 2026.
We developed a patient‐derived, functional microfluidic model of the diffuse midline glioma (DMG) blood–brain–tumor barrier (BBTB) comprised of endothelial cells, astrocytes, pericytes, and tumor cells. The system forms perfusable microvasculature, reveals the BBTB retains vascular integrity, identifies DMG‐specific transcriptomic changes distinct from
Kimberly R. Bennett, Yann S. Vanrobaeys, Tessy Teboh, Zakiya Smith, Anderson Scott, Cynthia Hajal, Paula T. Hammond, Joelle P. Straehla   +7 more
wiley   +1 more source

Drug interactions with the human organic anion transporter 3, OAT3 [PDF]

, 2009
As an active transporter of anionic molecules in the kidney, OAT3 plays a role in the renal elimination of many drugs and is also thought to be involved in drug-drug interactions in the kidney.
Munns, Denton R.
core  

Chicory (Cichorium intybus L.) inhibits renal reabsorption by regulating expression of urate transporters in fructose-induced hyperuricemia

Journal of Traditional Chinese Medical Sciences, 2019
Objective: Hyperuricemia is an excess of urate in blood. The kidneys play important parts in urate excretion, which involves handling reabsorption and secretion.
Yu Wang, Zhijian Lin, Bing Zhang, Xiao Wang, Mengzhen Chu   +4 more
doaj   +1 more source

Loss of the Kidney Urate Transporter, Urat1, Leads to Disrupted Redox Homeostasis in Mice

Antioxidants, 2023
High uric acid is associated with gout, hypertension, metabolic syndrome, cardiovascular disease, and kidney disease. URAT1 (SLC22A12), originally discovered in mice as Rst, is generally considered a very selective uric acid transporter compared to other
Neema Jamshidi, Kabir B. Nigam, Sanjay K. Nigam   +2 more
doaj   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development

Epilepsia, Volume 67, Issue 10, Page 5075-5125, October 2026.
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Organic anion transporters 1 (OAT1) and OAT3 meditated the protective effect of rhein on methotrexate-induced nephrotoxicity

, 2017
Rhein protects methotrexate induced kidney damage mediated by OAT1 and OAT3.
Huijun Sun, Xiaodong Ma, Kexin Liu, Changyuan Wang, Pengyuan Sun, Xiaobo Yang, Xiaokui Huo, Zhihao Liu, Yongming Jia, Qiang Meng, Jinyong Peng   +10 more
core   +1 more source

Population Pharmacokinetic Modeling of Glycochenodeoxycholic Acid 3-O-Sulfate (GCDCA-S) as Endogenous Biomarker of OATP1B3 and OAT3 Transporters. [PDF]

Clin Pharmacol Ther
Endogenous biomarkers for drug transporters are an emerging tool for the assessment of transporter-mediated drug–drug interactions (DDI). Glycochenodeoxycholic acid 3-O-sulfate (GCDCA-S) has been proposed as a Tier 2 biomarker of hepatic OATP1B3 and ...
Ujihira Y, Georgiev V, Ogungbenro K, Galetin A.   +3 more
europepmc   +2 more sources

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development

Epilepsia, Volume 67, Issue 10, Page 5042-5074, October 2026.
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Dual actions on gout flare and acute kidney injury along with enhanced renal transporter activities by Yokuininto, a Kampo medicine

BMC Complementary and Alternative Medicine, 2019
Background Prolonged hyperuricemia is associated with kidney disease or gouty arthritis. Whether Yokuininto, a commercially available Kampo medicine that has been used for osteoarthritis or rheumatoid arthritis, can exhibit anti-hyperuricemic and ...
Seung Hoon Lee, Ho-Sung Lee, Gunhyuk Park, Sung-Man Oh, Dal-Seok Oh   +4 more
doaj   +1 more source